Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory Bowel Disease (IBD)

Author(s): Tuula Peñate-Medina, Christabel Damoah, Miriam Benezra, Olga Will, Kalevi Kairemo, Jana Humbert, Susanne Sebens, Oula Peñate-Medina*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 31 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: The purpose of our study was to find a novel targeted imaging and drug delivery vehicle for inflammatory bowel disease (IBD). IBD is a common and troublesome disease that still lacks effective therapy and imaging options. As an attempt to improve the disease treatment, we tested αMSH for the targeting of nanoliposomes to IBD sites. αMSH, an endogenous tridecapeptide, binds to the melanocortin-1 receptor (MC1-R) and has anti-inflammatory and immunomodulating effects. MC1-R is found on macrophages, neutrophils and the renal tubule system. We formulated and tested a liposomal nanoparticle involving αMSH in order to achieve a specific targeting to the inflamed intestines.

Methods: NDP-αMSH peptide conjugated to Alexa Fluor™ 680 was linked to the liposomal membrane via NSuccinyl PE and additionally loaded into the lumen of the liposomes. Liposomes without the αMSH-conjugate and free NDP-αMSH were used as a control. The liposomes were also loaded with ICG to track them. The liposomes were tested in DSS treated mice, which had received DSS via drinking water order to develop a model IBD. Inflammation severity was assessed by the Disease Activity Index (DAI) score and ex vivo histological CD68 staining of samples taken from different parts of the intestine. The liposome targeting was analyzed by analyzing the ICG and ALEXA 680 fluorescence in the intestine compared to the biodistribution.

Results: NPD-αMSH was successfully labeled with Alexa and retained its biological activity. Liposomes were identified in expected regions in the inflamed bowel regions and in the kidneys, where MC1-R is abundant. In vivo liposome targeting correlated with the macrophage concentration at the site of the inflammation supporting the active targeting of the liposomes through αMSH. The liposomal αMSH was well tolerated by animals.

Conclusion: This study opens up the possibility to further develop an αMSH targeted theranostic delivery to different clinically relevant applications in IBD inflammation but also opens possibilities for use in other inflammations like lung inflammation in Covid 19.

Keywords: αMSH, DSS model, liposomes, fluorescence, targeting, IBD inflammation.

[1]
Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol 2019; 16(9): 531-43.
[http://dx.doi.org/10.1038/s41575-019-0172-4] [PMID: 31312042]
[2]
Hu G, Guo M, Xu J, et al. Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation. Front Immunol 2019; 21(10)
[http://dx.doi.org/10.3389/fimmu.2019.01998]
[3]
Singh M, Mukhopadhyay K. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide. BioMed Res Int 2014; •••2014874610
[http://dx.doi.org/10.1155/2014/874610] [PMID: 25140322]
[4]
Ericson MD, Freeman KT, Schnell SM, Haskell-Luevano C. A Macrocyclic Agouti-Related Protein/[Nle4,DPhe7]α-Melanocyte Stimulating Hormone Chimeric Scaffold Produces Subnanomolar Melanocortin Receptor Ligands. J Med Chem 2017; 60(2): 805-13.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01707] [PMID: 28045525]
[5]
Patel HB, Montero-Melendez T, Greco KV, Perretti M. Melanocortin receptors as novel effectors of macrophage responses in inflammation. Front Immunol 2011; 13(2): 41.
[http://dx.doi.org/10.3389/fimmu.2011.00041]
[6]
Kohda Y, Chiao H, Star RA. alpha-Melanocyte-stimulating hormone and acute renal failure. Curr Opin Nephrol Hypertens 1998; 7(4): 413-7.
[http://dx.doi.org/10.1097/00041552-199807000-00011] [PMID: 9690041]
[7]
Wei P, Yang Y, Ding Q, et al. Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis. J Med Microbiol 2016; 65(2): 160-8.
[http://dx.doi.org/10.1099/jmm.0.000197] [PMID: 26567174]
[8]
Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol 2010; 681: 107-16.
[http://dx.doi.org/10.1007/978-1-4419-6354-3_8] [PMID: 21222263]
[9]
Chen F, Zhang X, Ma K, et al. Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging. ACS Appl Mater Interfaces 2018; 10(5): 4379-93.
[http://dx.doi.org/10.1021/acsami.7b14362] [PMID: 29058865]
[10]
Etemad-Moghadam B, Chen H, Yin P, Aziz N, Hedley ML. Inhibition of NF-kappaB activity by plasmid expressed alphaMSH peptide. J Neuroimmunol 2002; 125(1-2): 23-9.
[http://dx.doi.org/10.1016/S0165-5728(02)00015-2] [PMID: 11960637]
[11]
Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev 2012; 64(13): 1394-416.
[http://dx.doi.org/10.1016/j.addr.2012.06.006] [PMID: 22728642]
[12]
Heneweer C, Gendy SE, Peñate-Medina O. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. Ther Deliv 2012; 3(5): 645-56.
[http://dx.doi.org/10.4155/tde.12.38] [PMID: 22834408]
[13]
Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30(11): 592-9.
[http://dx.doi.org/10.1016/j.tips.2009.08.004] [PMID: 19837467]
[14]
Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 2010; 62(11): 1052-63.
[http://dx.doi.org/10.1016/j.addr.2010.08.004] [PMID: 20709124]
[15]
Lee JB, Zhang K, Tam YY, et al. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer 2012; 131(5): E781-90.
[http://dx.doi.org/10.1002/ijc.27361] [PMID: 22095615]
[16]
Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2(3): 541-6.
[http://dx.doi.org/10.1038/nprot.2007.41] [PMID: 17406617]
[17]
Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp 2012; 3678(60)
[http://dx.doi.org/10.3791/3678] [PMID: 22331082]
[18]
Phillips E, Penate-Medina O, Zanzonico PB, et al. Clinical Translation of an Ultrasmall Optical Hybrid Nanoparticle Probe. Sci Transl Med 2014; 6(260)260ra149
[http://dx.doi.org/10.1126/scitranslmed.3009524] [PMID: 25355699]
[19]
Burns AA, Vider J, Ow H, et al. Fluorescent silica nanoparticles with efficient urinary excretion for nanomedicine. Nano Lett 2009; 9(1): 442-8.
[http://dx.doi.org/10.1021/nl803405h] [PMID: 19099455]
[20]
Benezra M, Peñate-Medina O, Zanzonico P, et al. Multimodal Silica Nanoparticles as Cancer-Targeted Probes in a Human Melanoma Model. J Clin Invest 2011; 121(7): 2768-80.
[http://dx.doi.org/10.1172/JCI45600] [PMID: 21670497]
[21]
Penate-Medina O, Penate-Medina T, Larson SM, Grimm J, Thorek DL, Kolesnick RN. inventors; Sloan-Kettering Institute for Cancer Research, assignee. Method for diagnosing or treating tumors using sphingomyelin containing liposomes. United States patent application US 14/162, 494. 2014 Jul 24


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 31
Year: 2020
Published on: 16 September, 2020
Page: [3840 - 3846]
Pages: 7
DOI: 10.2174/1381612826666200727002716
Price: $65

Article Metrics

PDF: 24
HTML: 3